Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 4Stomach Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Leukemia, Biphenotypic, Acute 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Burkitt Lymphoma 1Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 42Fluorouracil 27Capecitabine 24pembrolizumab 21S 1 (combination) 19Paclitaxel 19Leucovorin 16Nivolumab 13Docetaxel 13sintilimab 12Drug Therapy 12Trastuzumab 11tislelizumab 10Cisplatin 10Irinotecan 9Bevacizumab 8trastuzumab deruxtecan 7spartalizumab 7XELOX 7Surgical Procedures, Operative 7Radiotherapy 7Hyperthermic Intraperitoneal Chemotherapy 7Biopsy 7fludarabine 6disitamab vedotin 6Cyclophosphamide 6lenvatinib 5apatinib 5Specimen Handling 5Ramucirumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Stomach Neoplasms × Levoleucovorin × Clear all
NCT06793917 2025-07-20

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Fujian Cancer Hospital

Phase 3 Recruiting
269 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05319639 2025-02-27

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Fujian Cancer Hospital

Phase 1/2 Recruiting
51 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡